S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market
NYSE:AVNS

Avanos Medical (AVNS) Stock Price, News & Analysis

$18.71
+0.01 (+0.05%)
(As of 04/19/2024 ET)
Today's Range
$18.47
$18.98
50-Day Range
$18.51
$19.94
52-Week Range
$17.24
$31.31
Volume
183,669 shs
Average Volume
186,685 shs
Market Capitalization
$864.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.00

Avanos Medical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
65.7% Upside
$31.00 Price Target
Short Interest
Healthy
2.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of Avanos Medical in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$152,960 Sold Last Quarter
Proj. Earnings Growth
33.33%
From $1.38 to $1.84 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.88 out of 5 stars

Medical Sector

203rd out of 909 stocks

Surgical Appliances & Supplies Industry

9th out of 18 stocks

AVNS stock logo

About Avanos Medical Stock (NYSE:AVNS)

Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

AVNS Stock Price History

AVNS Stock News Headlines

Chances are you know the firms on this list
These are the entities that can buy MILLIONS of shares in a single day… I’m talking about huge orders that literally move the share price 1%, 2%, even 5% or more in the process. Why am I showing you that list? Well, because if you have a way to successfully detect which stocks these elite traders are likely buying in real time… All you have to do is ride the coattails of their massive orders and you can target endless trading opportunities without leaving your money exposed to the markets for too long. And in case you didn’t already know…
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
AVNS Mar 2024 20.000 call
Avanos Medical Q4 2023 Earnings Preview
Avanos Medical, Inc. (AVNS)
New Strong Sell Stocks for January 9th
New Strong Sell Stocks for January 12th
New Strong Sell Stocks for January 16th
Avanos Medical Warns of 4Q, 2024 Sales Shortfalls
See More Headlines
Receive AVNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2024
Today
4/21/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
N/A
Fax
N/A
Employees
3,771
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.00
High Stock Price Target
$31.00
Low Stock Price Target
$31.00
Potential Upside/Downside
+65.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-61,800,000.00
Pretax Margin
-1.17%

Debt

Sales & Book Value

Annual Sales
$673.30 million
Cash Flow
$2.02 per share
Book Value
$26.63 per share

Miscellaneous

Free Float
44,863,000
Market Cap
$864.40 million
Optionable
Optionable
Beta
0.96
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Joseph F. Woody (Age 58)
    CEO & Director
    Comp: $2.21M
  • Mr. Michael C. Greiner (Age 51)
    Senior VP, CFO & Chief Transformation Officer
    Comp: $986.42k
  • Ms. Mojirade James (Age 57)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $728.66k
  • Mr. Kerr W. Holbrook (Age 57)
    Senior VP & Chief Commercial Officer
    Comp: $747.61k
  • Mr. Sudhakar Varshney (Age 47)
    Senior Vice President of Global Supply Chain & Procurement
    Comp: $1.02M
  • Mr. John Joseph Hurley
    Principal Accounting Officer & Controller
  • Mr. David Crawford
    VP of FP&A and Investor Relations and Treasurer
  • Ms. Michelle Scharfenberg
    Senior VP and Chief Ethics & Compliance Officer
  • Mr. Scott Galovan
    Vice President of Strategy & Corporate Development
  • John W. Cato
    Vice President of Human Resources

AVNS Stock Analysis - Frequently Asked Questions

Should I buy or sell Avanos Medical stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AVNS shares.
View AVNS analyst ratings
or view top-rated stocks.

What is Avanos Medical's stock price target for 2024?

2 brokers have issued 1-year price targets for Avanos Medical's shares. Their AVNS share price targets range from $31.00 to $31.00. On average, they predict the company's stock price to reach $31.00 in the next year. This suggests a possible upside of 65.7% from the stock's current price.
View analysts price targets for AVNS
or view top-rated stocks among Wall Street analysts.

How have AVNS shares performed in 2024?

Avanos Medical's stock was trading at $22.43 at the beginning of the year. Since then, AVNS stock has decreased by 16.6% and is now trading at $18.71.
View the best growth stocks for 2024 here
.

Are investors shorting Avanos Medical?

Avanos Medical saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 1,180,000 shares, a decrease of 11.9% from the March 15th total of 1,340,000 shares. Based on an average daily trading volume, of 291,100 shares, the days-to-cover ratio is currently 4.1 days. Approximately 2.6% of the shares of the stock are short sold.
View Avanos Medical's Short Interest
.

When is Avanos Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our AVNS earnings forecast
.

How were Avanos Medical's earnings last quarter?

Avanos Medical, Inc. (NYSE:AVNS) posted its earnings results on Tuesday, February, 20th. The company reported $0.36 EPS for the quarter, missing the consensus estimate of $0.37 by $0.01. The company earned $173.30 million during the quarter, compared to analysts' expectations of $170.43 million. Avanos Medical had a negative net margin of 8.76% and a positive trailing twelve-month return on equity of 4.25%. The business's revenue for the quarter was down 4.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.60 EPS.

What ETF holds Avanos Medical's stock?

Invesco S&P SmallCap Health Care ETF holds 85,945 shares of AVNS stock, representing 0.78% of its portfolio.

What guidance has Avanos Medical issued on next quarter's earnings?

Avanos Medical issued an update on its FY 2024 earnings guidance on Friday, February, 23rd. The company provided earnings per share (EPS) guidance of 1.300-1.450 for the period. The company issued revenue guidance of $685.0 million-$705.0 million.

What is Joseph F. Woody's approval rating as Avanos Medical's CEO?

32 employees have rated Avanos Medical Chief Executive Officer Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among the company's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Avanos Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), RTX (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

Who are Avanos Medical's major shareholders?

Avanos Medical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Tributary Capital Management LLC (1.61%) and Maryland State Retirement & Pension System (0.04%). Insiders that own company stock include Julie Ann Shimer, Michael Greiner and Patrick J Oleary.
View institutional ownership trends
.

How do I buy shares of Avanos Medical?

Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:AVNS) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners